Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Change in Acquisitions & Divestments (2014 - 2021)

Mimedx recorded quarterly Change in Acquisitions & Divestments of $30000.0 in Q3 2021, little changed quarter-over-quarter from $30000.0 in Q2 2021.

Mimedx's Change in Acquisitions & Divestments history runs 6 years deep, the most recent figure standing at $30000.0 for Q3 2021.

In Q3 2021, Change in Acquisitions & Divestments changed N/A year-over-year to $30000.0; the TTM figure through Jun 2022 stood at $30000.0 (down 33.33% YoY), while the FY2021 annual figure was $75000.0, changed N/A from the prior year.
Change in Acquisitions & Divestments came in at $30000.0 for Q3 2021 at Mimedx, roughly flat from $30000.0 in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $2.3 million in Q3 2019 to a low of $15000.0 in Q1 2021.
A 3-year average of $595833.3 and a median of $209500.0 in 2019 frame the typical range for Change in Acquisitions & Divestments.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn
10	Mimedx	530.69 Mn	370.92 Mn	41.62 Mn

Historic Data

Download Data 🔒

Date	Value
Sep 30, 2021	30,000.00
Sep 30, 2021	30,000.00
Jun 30, 2021	30,000.00
Jun 30, 2021	30,000.00
Mar 31, 2021	15,000.00
Mar 31, 2021	15,000.00
Sep 30, 2019	2.33 Mn
Sep 30, 2019	2.33 Mn
Mar 31, 2019	389,000.00
Mar 31, 2019	389,000.00
Dec 31, 2018	778,000.00
Dec 31, 2018	778,000.00
Jun 30, 2016	2.50 Mn
Jun 30, 2016	2.50 Mn
Mar 31, 2016	500,000.00
Mar 31, 2016	500,000.00
Dec 31, 2015	3.50 Mn
Dec 31, 2015	3.50 Mn
Sep 30, 2015	750,000.00
Sep 30, 2015	750,000.00
Jun 30, 2015	1.25 Mn
Jun 30, 2015	1.25 Mn
Mar 31, 2015	500,000.00
Mar 31, 2015	500,000.00
Dec 31, 2014	-9.00 Mn
Dec 31, 2014	-9.00 Mn